S3 Table -

Table A: Population characteristics of the kidney cancer cases and controls from 5 independent cohorts with pre-diagnostic blood samples included in our analyses, by cohort. Table B: Description of the predefined sums and ratios of metabolites measured with the Biocrates assay as described in the manufacturer’s documentation. Table C: Genetic instruments associated with BMI used in 2-sample MR analyses. Table D: Genetic instruments associated with dental disease used in 2-sample MR analyses. Table E: Mean concentration of metabolites by case or control status (in μmol/L and raw area counts for Biocrates and Metablon, respectively). Table F: Associations between levels of circulating metabolites and kidney cancer risk adjusted for fasting status. Table G: Crude associations between levels of circulating metabolites and kidney cancer risk. Table H: Associations between levels of circulating metabolites and kidney cancer risk adjusted for risk factors (for metabolites robustly associated with kidney cancer risk in the crude analyses and restricted to participants with complete risk factor information). Table I: Association between BMI and circulating Biocrates metabolites from 2-sample MR analyses. Table J: Association between BMI and circulating Metabolon metabolites from 2-sample MR analyses. Table K: Association between dental disease and circulating Biocrates metabolites from 2-sample MR analyses. Table L: Association between dental disease and circulating Metabolon metabolites from 2-sample MR analyses. BMI, body mass index; MR, mendelian randomisation.
(XLSX)